Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC Bortezomib, Lenalidomide and Dexamethasone in Relapsed/Refractory MM
NCT01647165Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jul 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by National Cancer Institute. Planned start Jul 2012; status: withdrawn.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01647165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01647165.